| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Ann Thorac Surg 2004;77:942-949
© 2004 The Society of Thoracic Surgeons
a Department of Anesthesiology, Perioperative, and Pain Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA
b Department of Anesthesiology, University of Oklahoma, Oklahoma City, Oklahoma, USA
c Department of Cardiovascular Anesthesiology, Texas Heart Institute, Houston, Texas, USA
d Division of Cardiothoracic Surgery, University of Hawaii School of Medicine, Honolulu, Hawaii, USA
e Alexion Pharmaceuticals, Inc, Cheshire, Connecticut, USA
f Division of Cardiac Surgery, Procter and Gamble Pharmaceuticals, Mason, Ohio, USA
g Washington Hospital Center, Washington, DC, USA
h Department of Thoracic and Cardiovascular Surgery, Nebraska Heart Institute, Lincoln, Nebraska, USA
i Department of Anesthesiology, University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, Camden, New Jersey, USA
j Department of Anesthesia, Stanford University, Stanford, California, USA
k Multicenter Study of Perioperative Ischemia Research Group and the Ischemia Research and Education Foundation, San Francisco, California, USA
Accepted for publication August 19, 2003.
* Address reprint requests to Dr Shernan, Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital, Harvard Medical School, 75 Francis St, Boston, MA 02115, USA
e-mail: shernan{at}zeus.bwh.harvard.edu
BACKGROUND: During cardiac surgery requiring cardiopulmonary bypass, pro-inflammatory complement pathways are activated by exposure of blood to bio-incompatible surfaces of the extracorporeal circuit and reperfusion of ischemic organs. Complement activation promotes the generation of additional inflammatory mediators thereby exacerbating tissue injury. We examined the safety and efficacy of a C5 complement inhibitor for attenuating inflammation-mediated cardiovascular dysfunction in cardiac surgical patients undergoing cardiopulmonary bypass.
METHODS: Pexelizumab (Alexion Pharmaceuticals, Inc, Cheshire, CT), a recombinant, single-chain, anti-C5 monoclonal antibody, was evaluated in a randomized, double-blinded, placebo-controlled, multicenter trial that involved 914 patients undergoing coronary artery bypass grafting with or without valve surgery requiring cardiopulmonary bypass.
RESULTS: Pexelizumab was administered intravenously as a bolus (2.0 mg/kg) or bolus plus infusion (2.0 mg/kg plus 0.05 mg/kg/h for 24 hours), and inhibited complement activation. There were no statistically significant differences between placebo-treated and pexelizumab-treated patients in the primary endpoint (composite of death, or new Q-wave, or non-Q-wave [myocardial-specific isoform of creatine kinase > 60 ng/mL] myocardial infarction, or left ventricular dysfunction, or new central nervous system deficit). However, post hoc analysis revealed a reduction in the composite of death or myocardial infarction (myocardial-specific isoform of creatine kinase 
100 ng/mL) for the isolated coronary artery bypass grafting, bolus plus infusion subgroup on POD 4 (p = 0.007) and on POD 30 (p = 0.004).
CONCLUSIONS: Pexelizumab had no statistically significant effect on the primary endpoint. However, the reduction in death or myocardial infarction (myocardial-specific isoform of creatine kinase 100 ng/mL) as revealed in the post hoc analysis in the isolated coronary artery bypass grafting bolus plus infusion subpopulation, suggests that further investigation of anti-C5 therapy for ameliorating complement-mediated inflammation and myocardial injury is warranted.
This article has been cited by other articles:
|
|
 |
|
  L. Testa, W.J. Van Gaal, R. Bhindi, G.G.L. Biondi-Zoccai, A. Abbate, P. Agostoni, I. Porto, F. Andreotti, F. Crea, and A.P. Banning Pexelizumab in ischemic heart disease: a systematic review and meta-analysis on 15,196 patients. J. Thorac. Cardiovasc. Surg., October 1, 2008; 136(4): 884 - 893. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 MEND-CABG II Investigators* Efficacy and Safety of Pyridoxal 5'-Phosphate (MC-1) in High-Risk Patients Undergoing Coronary Artery Bypass Graft Surgery: The MEND-CABG II Randomized Clinical Trial JAMA, April 16, 2008; 299(15): 1777 - 1787. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. H. Rosner, D. Portilla, and M. D. Okusa Analytic Reviews: Cardiac Surgery as a Cause of Acute Kidney Injury: Pathogenesis and Potential Therapies J Intensive Care Med, January 1, 2008; 23(1): 3 - 18. [Abstract] [PDF]
|
|
|
|
 |
|
 H. L. Lazar, T. Keilani, C. A. Fitzgerald, O. M. Shapira, C. T. Hunter, R. J. Shemin, H. C. Marsh Jr, U. S. Ryan, and the TP10 Cardiac Surgery Study Group Beneficial Effects of Complement Inhibition With Soluble Complement Receptor 1 (TP10) During Cardiac Surgery: Is There a Gender Difference? Circulation, September 11, 2007; 116(11_suppl): I-83 - I-88. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Fattouch, G. Bianco, G. Speziale, R. Sampognaro, C. Lavalle, F. Guccione, P. Dioguardi, and G. Ruvolo Beneficial effects of C1 esterase inhibitor in ST-elevation myocardial infarction in patients who underwent surgical reperfusion: a randomised double-blind study Eur. J. Cardiothorac. Surg., August 1, 2007; 32(2): 326 - 332. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. M. Dyke, L. K. Jennings, G. Maier, C. Andreou, R. Daly, and M. R. Tamberella III Preoperative Platelet Inhibition With Eptifibatide During Coronary Artery Bypass Grafting With Cardiopulmonary Bypass Journal of Cardiovascular Pharmacology and Therapeutics, March 1, 2007; 12(1): 54 - 60. [Abstract] [PDF]
|
|
|
|
|
|
J. W. Eikelboom and M. O'Donnell Pexelizumab Does Not "Complement" Percutaneous Coronary Intervention in Patients With ST-Elevation Myocardial Infarction JAMA, January 3, 2007; 297(1): 91 - 92. [Full Text] [PDF]
|
|
|
|
 |
|
 C. S. Rinder, M. J. Smith, H. M. Rinder, D. N. Cortright, R. M. Brodbeck, J. E. Krause, and B. R. Smith Leukocyte Effects of C5a-Receptor Blockade During Simulated Extracorporeal Circulation Ann. Thorac. Surg., January 1, 2007; 83(1): 146 - 152. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. T. Lappegard Invited commentary Ann. Thorac. Surg., January 1, 2007; 83(1): 152 - 152. [Full Text] [PDF]
|
|
|
|
|
|
A. Haverich, S. K. Shernan, J. H. Levy, J. C. Chen, M. Carrier, K. M. Taylor, F. Van de Werf, M. F. Newman, P. X. Adams, T. G. Todaro, et al. Pexelizumab Reduces Death and Myocardial Infarction in Higher Risk Cardiac Surgical Patients Ann. Thorac. Surg., August 1, 2006; 82(2): 486 - 492. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Thielmann, G. Marggraf, M. Neuhauser, J. Forkel, U. Herold, M. Kamler, P. Massoudy, and H. Jakob Administration of C1-esterase inhibitor during emergency coronary artery bypass surgery in acute ST-elevation myocardial infarction. Eur. J. Cardiothorac. Surg., August 1, 2006; 30(2): 285 - 293. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. W. Sellke and M. Boodhwani Inhibition of complement activation in cardiac surgery J. Thorac. Cardiovasc. Surg., February 1, 2006; 131(2): 266 - 267. [Full Text] [PDF]
|
|
|
|
 |
|
 M. H. Rosner and M. D. Okusa Acute Kidney Injury Associated with Cardiac Surgery Clin. J. Am. Soc. Nephrol., January 1, 2006; 1(1): 19 - 32. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. S. Speidl, M. Exner, J. Amighi, S. P. Kastl, G. Zorn, G. Maurer, O. Wagner, K. Huber, E. Minar, J. Wojta, et al. Complement component C5a predicts future cardiovascular events in patients with advanced atherosclerosis Eur. Heart J., November 1, 2005; 26(21): 2294 - 2299. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Theroux, P. W. Armstrong, K. W. Mahaffey, J. S. Hochman, K. J. Malloy, S. Rollins, J. C. Nicolau, J. Lavoie, T. M. Luong, J. Burchenal, et al. Prognostic significance of blood markers of inflammation in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty and effects of pexelizumab, a C5 inhibitor: a substudy of the COMMA trial Eur. Heart J., October 1, 2005; 26(19): 1964 - 1970. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. F. Bonvini, T. Hendiri, and E. Camenzind Inflammatory response post-myocardial infarction and reperfusion: a new therapeutic target? Eur. Heart J. Suppl., October 1, 2005; 7(suppl_I): I27 - I36. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Ramsay, S. Shernan, J. Fitch, P. Finnegan, T. Todaro, T. Filloon, and N. A. Nussmeier Increased creatine kinase MB level predicts postoperative mortality after cardiac surgery independent of new Q waves J. Thorac. Cardiovasc. Surg., February 1, 2005; 129(2): 300 - 306. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. K. Eltzschig and C. D. Collard Vascular ischaemia and reperfusion injury Br. Med. Bull., October 19, 2004; 70(1): 71 - 86. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. P. Mathew, S. K. Shernan, W. D. White, J. C.K. Fitch, J. C. Chen, L. Bell, and M. F. Newman Preliminary Report of the Effects of Complement Suppression With Pexelizumab on Neurocognitive Decline After Coronary Artery Bypass Graft Surgery Stroke, October 1, 2004; 35(10): 2335 - 2339. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. L. Lazar, P. M. Bokesch, F. van Lenta, C. Fitzgerald, C. Emmett, H. C. Marsh Jr, U. Ryan, and OBE and the TP10 Cardiac Surgery Study Group Soluble Human Complement Receptor 1 Limits Ischemic Damage in Cardiac Surgery Patients at High Risk Requiring Cardiopulmonary Bypass Circulation, September 14, 2004; 110(11_suppl_1): II-274 - II-279. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. D. Verrier, S. K. Shernan, K. M. Taylor, F. Van de Werf, M. F. Newman, J. C. Chen, M. Carrier, A. Haverich, K. J. Malloy, P. X. Adams, et al. Terminal Complement Blockade With Pexelizumab During Coronary Artery Bypass Graft Surgery Requiring Cardiopulmonary Bypass: A Randomized Trial JAMA, May 19, 2004; 291(19): 2319 - 2327. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |
